Caribou Biosciences to Participate in Upcoming Investor Conferences
20 nov. 2024 16h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
19 nov. 2024 16h30 HE
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
06 nov. 2024 08h00 HE
|
Barinthus Biotherapeutics
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
31 oct. 2024 08h00 HE
|
Barinthus Biotherapeutics
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
25 sept. 2024 09h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract...
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
24 sept. 2024 08h00 HE
|
Barinthus Biotherapeutics
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody
03 sept. 2024 21h00 HE
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI and SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, Inc. (“EpimAb” or “EpimAb Biotherapeutics”) a clinical stage biopharmaceutical company specializing in the...
Autologous Cell Therapy Market Estimated to Grow USD 34.7 Billion by 2027, Rising at a 18.1% CAGR- Transparency Market Research, Inc.
21 août 2024 11h09 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. , Aug. 21, 2024 (GLOBE NEWSWIRE) -- According to Transparency Market Research (TMR), the global autologous cell therapy market...
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19 août 2024 08h00 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a biopharmaceutical company focused on developing and advancing...
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
19 août 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study